ANIP Q4 2023 Earnings — ANI Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

ANIPANI Pharmaceuticals, Inc.

$2B

Q4 2023 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$132M+39.7% YoY

Gross Profit

$78M59.4% margin

Operating Income

$7M5.1% margin

Net Income

$1M0.9% margin

EPS (Diluted)

$0.04

QoQ Revenue Growth

-0.1%

Cash Flow

Operating Cash Flow

$45M

Free Cash Flow

$40M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$904M

Total Liabilities

$447M

Stockholders' Equity

$458M

Cash & Equivalents

$221M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$132M	$94M	+39.7%
Gross Profit	$78M	$58M	+35.1%
Operating Income	$7M	$2M	+269.6%
Net Income	$1M	-$4M	+127.2%

Revenue Segments

Rare Disease

$199M64%

Sales of rare disease pharmaceutical products

$112M36%

Geographic Segments

United States

$132M100%